 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| CCI15106 / GSK
Trial completion: Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug (clinicaltrials.gov) - Jun 25, 2018
P1, N=52, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed
- || CCI15106 / GSK
Enrollment closed: Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug (clinicaltrials.gov) - May 31, 2018
P1, N=58, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | CCI15106 / GSK
Trial completion date: Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug (clinicaltrials.gov) - Mar 3, 2018
P1, N=58, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Trial completion date: Apr 2018 --> May 2018
- || CCI15106 / GSK
Trial primary completion date: Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug (clinicaltrials.gov) - Aug 30, 2017
P1, N=58, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: Apr 2018 --> May 2018 Trial primary completion date: Dec 2017 --> Mar 2018
- CCI15106 / GSK
New P1 trial: Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients (clinicaltrials.gov) - Aug 8, 2017
P1, N=60, Terminated, Sponsor: GlaxoSmithKline
- ||| CCI15106 / GSK
New P1 trial: Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug (clinicaltrials.gov) - Jul 31, 2017
P1, N=58, Recruiting, Sponsor: GlaxoSmithKline